From the Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Clin Nucl Med. 2019 Oct;44(10):777-783. doi: 10.1097/RLU.0000000000002694.
Somatostatin receptor (SSTR) PET has become a mainstay in the diagnosis of neuroendocrine tumors (NETs) and for selecting patients for SSTR-based therapy; however, no consensus has yet been reached in terms of prognosis. A systematic review and meta-analysis was performed on the prognostic value of the maximum standardized uptake value (SUVmax) for Ga-SSTR PET in patients with NETs.
We performed a systematic search using the following keywords: PET, SSTR, NET, and prognosis. The inclusion criteria were the use of Ga-SSTR PET as an imaging tool, studies limited to NETs, studies that reported progression-free survival (PFS) and/or overall survival (OS), and studies that included SUVmax as a prognostic parameter. The effect of SUVmax on PFS and OS was measured in terms of the hazard ratio (HR).
Eight eligible studies with 474 patients were finally included and analyzed. The combined HR of SUVmax on PFS was 2.31 with significance (95% confidence interval [CI], 1.34-4.00; P = 0.003). The trim and fill adjusted analysis for SUVmax on PFS demonstrated the combined HR as 1.81 with significance (95% CI, 1.11-2.95; P = 0.017), as the publication bias was found (Egger P = 0.004). The combined HR of SUVmax on OS was 2.97 with significance (95% CI, 1.71-5.15; P = 0.0001), without publication bias (Egger P = 0.929). The subgroup analysis revealed that well-differentiated NETs (grade 1 or 2) on PFS showed significance (P = 0.03); however, all grades of NETs (including grade 3) on PFS did not reach significance (P = 0.11). Tumor site and type of radiotracer did not affect the prognostic value of SUVmax.
Low SUVmax of Ga-SSTR PET was associated with a worse prognosis for PFS and OS in patients with NETs. Well-differentiated NETs had more prognostic value compared with all grades of NETs. The SUVmax of Ga-SSTR PET could be used as an objective prognosis predictor.
生长抑素受体(SSTR)PET 已成为神经内分泌肿瘤(NETs)诊断和 SSTR 为基础的治疗选择患者的主要方法;然而,在预后方面尚未达成共识。我们对 Ga-SSTR PET 在 NET 患者中的最大标准化摄取值(SUVmax)的预后价值进行了系统回顾和荟萃分析。
我们使用以下关键词进行了系统搜索:PET、SSTR、NET 和预后。纳入标准是将 Ga-SSTR PET 用作成像工具、仅限于 NETs 的研究、报告无进展生存期(PFS)和/或总生存期(OS)的研究,以及将 SUVmax 作为预后参数的研究。SUVmax 对 PFS 和 OS 的影响通过风险比(HR)进行测量。
最终纳入并分析了 8 项符合条件的研究,共 474 例患者。SUVmax 对 PFS 的合并 HR 为 2.31,具有显著性(95%置信区间 [CI],1.34-4.00;P=0.003)。SUVmax 对 PFS 的修剪和填充调整分析显示,合并 HR 为 1.81,具有显著性(95%CI,1.11-2.95;P=0.017),因为存在发表偏倚(Egger P=0.004)。SUVmax 对 OS 的合并 HR 为 2.97,具有显著性(95%CI,1.71-5.15;P=0.0001),无发表偏倚(Egger P=0.929)。亚组分析显示,PFS 时分化良好的 NETs(1 或 2 级)具有显著性(P=0.03);然而,所有 NETs 分级(包括 3 级)在 PFS 时均未达到显著性(P=0.11)。肿瘤部位和放射性示踪剂类型不影响 SUVmax 的预后价值。
Ga-SSTR PET 的低 SUVmax 与 NET 患者的 PFS 和 OS 预后较差相关。分化良好的 NETs 比所有 NETs 分级都具有更高的预后价值。Ga-SSTR PET 的 SUVmax 可作为客观的预后预测指标。